•Treatment of sex-cord stromal tumors with carboplatin and taxane is both feasible and safe.•FOXL2 mutations account for approximately 50% of these tumors.•Carboplatin and taxane may afford a favorable outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688826 | PMC |
| http://dx.doi.org/10.1016/j.gore.2015.08.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A molecular and immunohistochemical study of 37 cases of ovarian Sertoli-Leydig cell tumor.
Virchows Arch
November 2024
Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Article Synopsis
- This study analyzes 37 ovarian Sertoli-Leydig cell tumors (SLCT) with a focus on their morphology, immunohistochemistry, and molecular features, categorizing them into well, moderately, and poorly differentiated tumors.
- High levels of sex cord markers were found, along with variable expression of other markers, and notable mutations like DICER1 (54.5%) and FOXL2 (6%) were identified, suggesting important diagnostic and predictive implications.
- Differences in mRNA expression profiles between DICER1 and non-DICER1 tumors highlight the distinct molecular characteristics of SLCTs, indicating that well-differentiated tumors could represent a unique subtype apart from the others.
Does surgery to preserve fertility in Sertoli-Leydig cell tumours increase the likelihood of spontaneous conception?
BMJ Case Rep
October 2024
Reproductive Medicine & Surgery, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
Article Synopsis
- A woman in her 30s experienced primary infertility and secondary amenorrhoea, with signs of virilisation and a solid mass found on her right ovary, leading to concerns about an ovarian tumor.
- Tests indicated the likely presence of an androgen-producing tumor called a Sertoli-Leydig cell tumour (SLCT), which was confirmed through histopathology after a fertility-sparing surgery.
- Following the surgery, the patient’s testosterone levels dropped significantly, and her menstrual cycle resumed, highlighting the importance of recognizing SLCTs in similar cases and considering fertility-preserving options in young women with such conditions.
An Ovarian Sertoli-Leydig Cell Tumor with Elevated Alpha-Fetoprotein in an Adolescent: A Rare Case Report and Literature Review.
Medicina (Kaunas)
September 2024
Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
An ovarian Sertoli-Leydig cell tumor is a rare type of sex cord-stromal tumor of the ovary. Typically, it presents as abdominal pain or androgenic manifestations in women in the second to third decade of life. While cases of ovarian Sertoli-Leydig cell tumor associated with increased levels of alpha-fetoprotein are rare, they are reported to be the most common alpha-fetoprotein-producing ovarian non-germ cell tumor.
View Article and Find Full Text PDFCharacteristics and prognostic implications of a cohort of 50 Sertoli-Leydig cell tumors at a single center.
Int J Gynaecol Obstet
February 2025
National Clinical Research Center for Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- - The study analyzed 50 cases of Sertoli-Leydig cell tumors (SLCTs) to understand their clinical features, treatment methods, and outcomes, finding that the majority of patients were under 45 years old.
- - Results showed that 90% of patients achieved clinical remission, with the prognosis being generally favorable for early-stage tumors, while advanced and aggressive variants experienced worse outcomes.
- - The research suggests that fertility-sparing surgery is a viable treatment option for patients with early-stage SLCTs, with some patients successfully giving birth to healthy babies post-treatment.
The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors.
Diagn Pathol
August 2024
Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, Prague 2, 12800, Czech Republic.
Background: Stathmin, a cytosolic microtubule-destabilizing phosphoprotein involved in the regulation of mitosis, is widely expressed in various malignancies and acts as an adverse prognostic factor. Our research analyzed its immunohistochemical expression on a large cohort of ovarian sex cord-stromal tumors, evaluating its potential utility in differential diagnosis, prognosis, and therapeutic application.
Methods: We examined 390 cases of ovarian sex cord-stromal tumors including 281 adult granulosa cell tumors (AGCT), 5 juvenile granulosa cell tumors (JGCT), 33 Sertoli-Leydig cell tumors (SLCT), 50 fibromas/thecomas (F/T), 11 Leydig cell tumors/steroid cell tumors (LCT/SterCT), 5 sex-cord stromal tumors NOS (SCST-NOS), 3 Sertoli cell tumors (SCT), and 2 sclerosing stromal tumors (ScST).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!